Vaccine News and Research

Latest Vaccine News and Research

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

A new research paper posted to the preprint server medRxiv* reports the rise of a new lineage in Tokyo, Japan, bearing a combination of two biologically important mutations.

20 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

FDA reminds the public about the limitations of COVID-19 antibody

The following quote is attributed to Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Childhood immunization rates in Texas declined sharply during COVID-19 pandemic

Despite expert recommendations that children continue to get regularly scheduled vaccines during the pandemic, vaccination rates have decreased in several states.

20 May 2021

Philly CEAL team receives NIH grant to extend COVID-19 outreach

José A. Bauermeister, PhD, and Antonia M. Villarruel, PhD, are leading one of 10 new research teams from across the country that received National Institutes of Health (NIH) grants totaling $14 million to extend the reach of the NIH's Community Engagement Alliance (CEAL) Against COVID-19 Disparities.

20 May 2021

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Researchers in the UK have demonstrated the efficacy of the Pfizer-BioNTech and AstraZeneca vaccines against severe acute respiratory virus coronavirus 2 (SARS-CoV-2) at preventing death among older individuals with coronavirus disease 2019 (COVID-19).

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

The effects of SARS-CoV-2 vaccination on pregnancy and birth

The severe impact of this infection has given rise to a study by Theiler et al. (2021), which investigated the effects of SARS-CoV-2 vaccination in pregnancy in order to examine the protection it could provide to combat the infection.

19 May 2021

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Scientists have recently investigated the dynamics of immune responses in elderly people who have received two doses of the Pfizer/BioNTech COVID-19 vaccine.

19 May 2021

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

Once dismissed as a conspiracy theory, the idea that the covid virus escaped from a Chinese lab is gaining high-profile attention. As it does, reputations of renowned scientists are at risk — and so is their personal safety.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Sequentia Biotech and NextBiomics announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.

From Sequentia Biotech 19 May 2021

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

A new study has been published on the medRxiv* preprint server which focuses on validating the serological assays using a large cohort of healthcare workers.

19 May 2021

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

New research published on the preprint server bioRxiv* performed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic simulations to understand the evolutionary transition from a bat-adapted SARS-CoV-2 to a human-adapted virus.

19 May 2021

Latest round of REACT-1 finds SARS-CoV-2 prevalence has halved since previous round

Researchers in the UK say the latest round of the REal-time Assessment of Community Transmission-1 (REACT-1) study has found that the prevalence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – has fallen by 50%, compared with the previous round conducted in March of this year (2021).

19 May 2021

Vaccine News and Research

Latest Vaccine News and Research

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

FDA reminds the public about the limitations of COVID-19 antibody

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Childhood immunization rates in Texas declined sharply during COVID-19 pandemic

Philly CEAL team receives NIH grant to extend COVID-19 outreach

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

The effects of SARS-CoV-2 vaccination on pregnancy and birth

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Spike antibodies after vaccination with Pfizer and Oxford vaccines

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

Latest round of REACT-1 finds SARS-CoV-2 prevalence has halved since previous round

Study validates predictive model for identifying pediatric patients at risk for developing blood clots

Researchers found disparities for COVID-19 testing and positivity rates in West Virginia

Combination approach can improve the success rate of cancer treatment

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in